PAYVANDI, FLORA
PAYVANDI, FLORA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Diverse career paths within thrombosis and hemostasis: perspectives from the ISTH early career committee
2026 J.S. Gauer, N. Potere, T. Chiasakul, S.D. Manevski, S. Kohli, F. Peyvandi, P. Armstrong, T. Chiasakul, S.D. Manevski, A. Iding, S. Kohli, N. Potere, J.S. Gauer, Z. Sayar, S. Sewaralthahab, R. Zon, L. Poole, R. Eslick
Orthopaedic Surgery Outcomes in Patients With Haemophilia A or B Treated With Extended Half‐Life Recombinant Factor VIII and IX Fc Fusion Proteins: A Multicentre Prospective Study
2025 L.P. Solimeno, R. Gualtierotti, E. Guido, J. Acquati Lozej, E. Cristini, A. Ciavarella, S. Arcudi, C. Carulli, L. Pieri, S.M. Siboni, F. Peyvandi
Development of a novel gene editing lexicon for hemophilia: methodology and results
2025 C.M. Kessler, L.A. Valentino, C.D. Thornburg, C. Unzu, M.A. Kay, F. Peyvandi, P. Smith, W. Miesbach, W. Mckeown, G.F. Pierce, K. Khair, K. Starcevic, M. Pillai, M. Jones, A. Sindhurakar, L. Whyte, V. Delwart, M. Chiao, D.E. Gutstein, I. Antonino, C. Hermans, S.W. Pipe
Thrombin Generation Assays: What are the Current Clinical Applications?
2025 A. Tripodi, M. Clerici, E. Scalambrino, F. Peyvandi
More on the pathogenesis of thrombotic thrombocytopenic purpura. Comment on “Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism” and on “The different faces of thrombotic thrombocytopenic purpura”
2025 F. Peyvandi
Qualification Criteria of Gene Therapy for Haemophilia-Opinion of the EAHAD Gene Therapy Working Group
2025 W. Miesbach, A. Boban, P. Chowdary, M. Coppens, V. Jimenez-Yuste, R. Klamroth, G. Mulders, M. Crato, F. Peyvandi
The risk of cerebral vein thrombosis associated with different types of combined hormonal contraceptives: a case-control study
2025 M. Abbattista, A. Truma, I. Martinelli, F. Gianniello, S.M. Passamonti, M. Capecchi, A. Artoni, F. Peyvandi, P. Bucciarelli
A-SURE: intra-patient comparison of prophylactic effectiveness of a recombinant factor VIII Fc fusion protein versus standard half-life factor VIII in hemophilia A
2025 J. Oldenburg, C. Hay, F. Peyvandi, A. Lehtinen, I. Pabinger, E. Nüesch, H. Malmström, E. Bednar, S. Lethagen
Gene Therapy for Hemophilias: Opportunities and Challenges for the Clinical Laboratory
2025 A. Tripodi, I. Garagiola, N. Bitto, V. La Mura, F. Peyvandi
Bortezomib for rituximab-refractory immune-mediated thrombotic thrombocytopenic purpura in the caplacizumab era: an Italian multicenter study
2025 J.A. Giannotta, A. Artoni, I. Mancini, P. Agosti, M. Carpenedo, A. Truma, S. Miri, B. Ferrari, P. De Leo, P. Salutari, G. Mancini, A. Molteni, E. Rinaldi, M. Bocchia, M. Napolitano, L. Prezioso, A. Cuccaro, E. Scarpa, A. Condorelli, D. Grimaldi, M. Massaia, F. Peyvandi
Thrombotic thrombocytopenic purpura: early diagnosis and effective treatment in 2025
2025 E. Azoulay, A. Veyradier, S. Cataland, B.S. Joly, P. Knoebl, L. Zafrani, J. Wendon, F. Fakhouri, B. Lämmle, K. Pavenski, N. Biebuyck, K. Vanhoorelbeke, S. Chaturvedi, A.M. Pishko, K. Donadello, M. Scully, M. Matsumoto, F. Peyvandi, M.E. Mingot-Castellano, X.L. Zheng, E. Mariotte, Y. Benhamou, P. Coppo
Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study
2025 G. Young, K. Kavakli, R. Klamroth, T. Matsushita, F. Peyvandi, S.W. Pipe, S. Rangarajan, M. Shen, A. Srivastava, J. Sun, H. Tran, C. You, B. Zülfikar, L.A. Menapace, C. Zhang, Y. Shen, M. Puurunen, M. Demissie, G. Kenet
Design organization and clinical processes around patient characteristics: Evidence from a multiple case study of Hemophilia
2025 S. Villa, R. De Cristofaro, G. Di Minno, S. Laratro, F. Peyvandi, L. Pippo, S. Villa, A.G. De Belvis
Therapeutic plasma exchange-related complications in patients with immune-mediated thrombotic thrombocytopenic purpura: Complications of therapeutic plasma-exchange
2025 P. Agosti, I. Mancini, A. Artoni, C. Cardone, P. De Leo, C. Bichard, A. Truma, B. Ferrari, J.A. Giannotta, N.N. Fantini, M.C. Mocellin, D. Prati, F. Peyvandi
Operationalising a Haemophilia Gene Editing Lexicon for Practical Use
2025 W. Mckeown, C. Hermans, C. Unzu, M.A. Kay, F. Peyvandi, P. Smith, W. Miesbach, G.F. Pierce, K. Khair, L.A. Valentino, S.W. Pipe, M. Pillai, M. Jones, V. Delwart, A. Sindhurakar, D.E. Gutstein, C.M. Kessler
Global prevalence of platelet-type von Willebrand disease
2025 O. Seidizadeh, A. Cairo, M. Othman, F. Peyvandi
Adeno-associated virus-based gene therapy for hemophilia–addressing the gaps
2025 W. Miesbach, P. Batty, P. Chowdary, S. Fong, R. Kaczmarek, F.W.G. Leebeek, B. Long, J. Mahlangu, M. Makris, G.F. Pierce, S.W. Pipe, A. Srivastava, J. Voorberg, F. Peyvandi
Gene therapy in hemophilia: the dawn of a new era
2025 R. Gualtierotti, A. Giachi, N. Bitto, V. La Mura, F. Peyvandi
Trends in Treatment of Severe Haemophilia and Impact on Inhibitor Assessment by the EUHASS Registry
2025 K. Fischer, R. Lassila, F. Peyvandi, A. Gatt, S.C. Gouw, R. Hollingsworth, T. Lambert, R. Kaczmarek, D. Carbonero, M. Makris
Challenges and considerations of genetic testing in von Willebrand disease
2025 O. Seidizadeh, L. Baronciani, F. Peyvandi